Kardium Announces Completion of Paroxysmal Enrollment in the PULSAR IDE Study
VANCOUVER, British Columbia, April 02, 2024--Kardium Inc., a private medical device company that has developed the Globe® System for the treatment of atrial fibrillation (AF) using pulsed field ablation (PFA), announced today the successful completion of enrollment in the paroxysmal cohort of the pivotal PULSAR IDE (Investigational Device Exemption) study. This achievement marks a significant milestone in the journey to bring this groundbreaking technology to patients in the United States, with
Source: yahoo.com